Xavier Morelli
  • E-mail :[email]
  • Phone : +33 486 977 331
  • Location : Marseille, France
Last update 2015-05-22 17:04:20.726

Xavier Morelli Group Leader in Structure-Based Drug Design - CRCM Marseille

Course and current status

SHORT RESUME:

  • Research Director (DR2), CNRS
  • Group Leader – Cancer Research Center of Marseille (CRCM)
Targeting Protein-Protein interaction in cancer signaling & Epigenetics using integrated structural & chemical biology

  • Member of the National Academic Screening Platforms ‘AD2P’
In charge of the Chemoinformatics (Chemical Libraries Selection), Hit validation - Hit to Lead optimization  

  • Secretary of the French Society of ChemoInformatics (SFCi)
  • Scientific committee member of the National Foundation ‘ARC’ (national agency against cancer)
  • Board of expert at the French Society of Medicinal Chemistry
  • Board of expert at the ‘Epigenetics’ AVIESAN consortium (French Minister of Research).
  • Board of expert at the Aix-Marseille University PhD Doctoral School of Chemistry
  • Associate Editor of the Scientific Journal “BMC Pharmacology & Toxicology”
  • Regular Consultant for pharmaceutical companies since 2009 
  • 11 Grants as coordinator or participant (5 running)

EDUCATION:

  • May 2008      Habilitation à Diriger des Recherches - Aix-Marseille University

  • 1997-2000    PhD, University of PARIS XI
Dr. Mireille Bruschi’s Laboratory, (UPR9036 - Marseille, France).  
PhD Advisor: Dr. Françoise Guerlesquin

  • 1995-1996    Master’s Degree - University of Paris XI
Crystallography and Biological NMR, Concepts and Methods. (rank: 1st)

  • 1994-1995    Bachelor’s Degree – Aix-Marseille University
Biochemistry majoring in Biophysics (NMR, EPR, X-RAYS) (rank: 1st/76)

Scientific summary

PROFESSIONAL EXPERIENCES: 

  • Present Research Director (DR2), CNRS.
Group Leader of the group iSCB ‘integrative Structural & Chemical Biology” at the Cancer Research Center of Marseille (CRCM, CNRS UMR7258 – INSERM U1068). 
 20 persons: 8 permanent researchers (3 DR2, 3 CR1, 1CR2 and 1 MCU), 1 technician in bioinformatics, 1 technician in organic chemistry, 2 technicians in biochemistry and cellular biology, 3 postdoctorates, 4 PhD students, 1 undergraduate student.

Principal focus of the group:
Identify, validate, understand and target protein-protein interaction in cancer cell signaling & epigenetic processes. 

  • 2008-2012         Group Leader of the group ID3 “Interaction, Dynamics and Drug Design” at the IMR laboratory (CNRS FRE3083) involving 12 persons: 3 permanent researchers (CR1), 1IT support, 1 technician in bio-informatics, 1 technician in biochemistry, 3 Post-doctorate and 3 PhD students.
  • 2002 – 2007       Principal Investigator - CNRS (National Center for the Scientific Research) FRANCE.
  • 2000-2002          Postdoctorate at Harvard Medical School (Pr Bruce Furie - Chief, Division of Hemostasis and Thrombosis, BIDMC).

STUDENT & POSTDOCTORAL MANAGEMENT
*Thesis n=6 as PhD advisor
*Postdoctorate n=5 as direct advisor

GRANTS:
  • 11 Grants as coordinator or participant (5 running):
- CNRS - Program 'PIR' (Coordinator): 2010
- Aix-Marseille University - Fond Incitatif de Recherche 'FIR' (Coordinator): 2010
- Fondation pour la Recherche Médicale - FRM (Coordinator): 2010/11
- Private Grant from Pharmaceutical Company ‘ValiRX’ (Coordinator): 2010/11
Private Grant from Pharmaceutical Company ‘IdRS’ (Coordinator): 2010/11
- INSERM Transfert ‘COPoC’ (Partner): 2013/14
- Institut National du Cancer - INCa 'Program PAIR Prostate' (Partner): 2010/14
- Région PACA (Partner): 2012/14 & 2015/17
- ANR 'Program Blanc' (Partner): 2013/16
- Institut National du Cancer - INCa 'Program PLBio' (Partner): 2013/17
- Fondation ARC 'Programme Libre' (Partner): 2014/17
- Program 'A*MIDEX' Aix-Marseille University (Partner): 2015-2017

CONSULTING / REVIEWING ACTIVITIES:
  • Expert for serveral National (ANR, French Ministry of Research, Region) and International (Neterland 'NWO', Singapore 'A*STAR', Ireland 'INA') agencies.
  • Expert / Consultant / Conference for several pharmaceutical companies (J&J, Merck-Serono, Tibotec, Hybrigenics, Institut de Recherche Servier, Laboratoires Fournier)

PUBLICATIONS: (H Index = 15)
  • 50 Publications (3 submitted)
  • 2 book chapters. 3 international patents (1 submitted).

CONFERENCES:
  • 50 INVITED CONFERENCES SINCE 2006 – 25 INTERNATIONAL, 25 NATIONAL
  • 3 Round Table Animation.
  • 2 Chairman session in International Conferences.
  • 6 conferences in Pharmaceutical companies (J&J, Merck-Serono, Hybrigenics, Tibotec, Servier, Abbott)
  • 3 Workshops as teacher: 2 INSERM and 1 CNRS
  • Invited to two EMBO workshops as teacher in 2012
  • Invited to the International School of Chemoinformatics as teacher in 2012
  • Invited to a European Federation of Medicinal Chemistry – Short Course - as teacher in 2015
Image d’exemple